Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ispinesib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 known ✓ | P52732 | 15/20 | 1.00 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.93 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.63 |
| ▸ | PDE6D | O43924 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ispinesib SCHEMBL29711229 | 1.00 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL29375933 | 0.96 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL15810599 | 0.96 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL3582165 | 0.96 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL370194 | 0.96 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL6360968 | 0.90 | KIF11 (0.87) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL6349230 | 0.90 | KIF11 (0.87) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL14264772 | 0.90 | KIF11 (0.87) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL16096544 | 0.89 | KIF11 (0.83) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL15764740 | 0.89 | KIF11 (0.83) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763628-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2010-07-27 | — | — | US | claimed |
| US-20070254902-A1 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. | 2007-11-01 | — | — | US | claimed |
| US-20150352114-A1 | MITOTIC KINESIN Eg5 INHIBITING ANTICANCER AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2015-12-10 | — | — | US | disclosed |
| EP-2582682-B1 | MITOTIC KINESIN INHIBITORS FOR USE IN THE TREATMETNOF PULMONARY ARTERIAL HYPERTENSION | CYTOKINETICS INC (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. | 2013-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352114-A1 | MITOTIC KINESIN Eg5 INHIBITING ANTICANCER AGENTS | KIF15, KIF5B, KIF18A | KIF11 9/4885MAP1LC3B 180/4885KCNH2 2347/4885 |
| US-20070254902-A1 | Methods and compositions utilizing quinazolinones | KIF5B, KIF5C, KIF2C | KIF11 22/4885MAP1LC3B 79/4885KCNH2 1101/4885 |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | KIF5B, KIF2C, KIF18B | KIF11 12/4885MAP1LC3B 106/4885KCNH2 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.